Laura Sepp-Lorenzino, PhDBiotech Executive, Board Member and Industry Advisor at GNMmeds LLCSpeaker
Profile
Laura Sepp-Lorenzino, Ph.D., is a biotechnology executive and board director with deep expertise in genomic medicine and nucleic acid therapeutics. She is Principal of GNMmeds LLC, advising on genomic medicine R&D and strategy. Laura serves on the boards of Taysha Gene Therapies, AskBio, URSA Medicines, OTS, and ASGCT. Previously, she was Chief Scientific Officer at Intellia Therapeutics (2019–2025), where she helped establish the first clinical proof of in vivo genome editing and advanced multiple programs into pivotal trials. Earlier, she held senior leadership roles at Vertex, Alnylam, and Merck, following foundational research training at Memorial Sloan-Kettering. She earned her degrees in biochemistry from the University of Buenos Aires and New York University.
Agenda Sessions
From Sequence to Therapy: Innovations in Oligonucleotide and Genome Editing Medicines
, 1:45pmView Session